Andreas Reinisch is a physician-scientist with a scientific interest focusing on the investigation of the genetic and molecular events leading to leukemia, with a particular emphasis on the contribution of the bone marrow microenvironment (aka niche). In their research, he and his inter-disciplinary team aim to reconstruct leukemogenic events in normal hematopoietic stem and progenitor cells using CRISPR/Cas9 technology. Thereby, they elucidate how individual mutations contribute to the formation of leukemic stem cells and eventually lead to frank leukemia. The Reinisch group furthermore investigates how the bone marrow niche interacts with normal and malignant hematopoietic cells and how niche cells contribute to leukemogenesis or themselves may get altered by leukemia. In order to address these specific questions, they develop novel humanized mouse models and gene-editing technology customized for primary human tissue.